Safety and Effectiveness of Mechanical Thrombectomy Using the Anaconda ANA5 Device (ATHENA)

April 15, 2024 updated by: Anaconda Biomed S.L.

A Prospective, Randomized, Dual-arm Multi-center Study to Assess the Safety and Effectiveness of Mechanical Thrombectomy Using the Anaconda ANA5 Device in Combination With a Stent Retriever

The objective of this study is to assess the safety and effectiveness of mechanical thrombectomy using the ANA funnel catheter to treat people with acute ischemic stroke within 24 hours of symptom onset. The device facilitates the placement of other devices such as stent retrievers and intravascular catheters during the procedure.

Study Overview

Detailed Description

The objective of this prospective randomized study is to assess the primary safety and effectiveness of mechanical thrombectomy (MT) using the ANA funnel catheter in its intended use as a device to facilitate the insertion and deployment of other devices (i.e., stent retrievers and intravascular catheters) and to allow flow restriction during MT procedures performed in subjects experiencing acute ischemic stroke (AIS) secondary to large vessel occlusion (LVO) of the internal carotid artery (ICA) and treated within 24 hours of symptom onset.

Acute reperfusion success after one pass (First Pass Effect, FPE) with ANA will be compared to an active control using the same stent retrievers delivered by an approved guide catheter with or without an intermediate catheter per conventional techniques. The study is designed to demonstrate that the use of ANA does not adversely impact the safety and effectiveness of a conventional stent retriever MT procedure.

Similar to other ancillary devices used in MT, the ANA device is designed to facilitate the delivery of stent retrievers and other catheters during these procedures. Its design aims to enhance procedural success and efficiency of stent retriever-based MT procedures by facilitating flow arrest during clot retrieval. This approach has been shown to improve rates of revascularization and good clinical outcome after three months. Numerous studies have established the value of flow arrest during MT, yet it is only used in a minority of procedures most likely due to concerns related to navigability, complexity and safety of the currently available devices.

Use of the ANA to facilitate MT with a stent retriever may provide a simplified approach to flow restriction, and may achieve similar acute reperfusion outcomes to commonly used approaches that combine direct aspiration with an intermediate catheter to actuate clot retrieval with a stent retriever (control). The study will report acute reperfusion success after a single thrombectomy pass with three of the most commonly employed stent retrievers, namely Solitaire, Trevo and pRESET. Procedural safety will be assessed by comparing the rate of procedure related sICH within 24 hours of the intervention between study arms.

Study Type

Interventional

Enrollment (Estimated)

250

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Key Inclusion Criteria:

  1. A new focal disabling neurologic deficit consistent with acute cerebral ischemia.
  2. Baseline National Institutes of Health Stroke Scale (NIHSS) obtained prior to procedure ≥ 8 points and ≤ 25 points.
  3. Pre-ictal modified Rankin Score (mRS) score of 0,1 or 2.
  4. Treatable within 24 hours of symptom onset, defined as point in time when the subject was last observed to be asymptomatic; treatment start is defined by arterial puncture time.
  5. Subjects received thrombolytic therapy in accordance with American Heart Association/American Stroke Association (AHA/ASA) Guidelines within 3 hours of symptom onset unless contraindicated.
  6. Occlusion (eTICI ≤ 1 flow) of the terminal carotid artery, middle cerebral artery (M1) or dominant proximal M2 segment, indicated for mechanical thrombectomy, confirmed with conventional angiography or Computed Tomographic Angiography/Magnetic Resonance Angiography (CTA/MRA).

Key Exclusion Criteria:

  1. Subject was diagnosed with a stroke in the past year.
  2. Clinical symptoms suggestive of bilateral stroke or stroke in multiple territories.
  3. Severe, sustained uncontrolled hypertension refractory to treatment (systolic blood pressure >185 mmHg or diastolic blood pressure >110 mmHg).
  4. Known pregnancy and/or lactating female.
  5. CT or MRI evidence of hemorrhage (the presence of microbleeds is allowed).
  6. Significant mass effect with midline shift.
  7. Evidence of intracranial tumor (except small meningioma).
  8. History of preexisting stent proximal to or at the occlusion site that may preclude safe deployment or recovery of the stent retriever.
  9. Vessel tortuosity too difficult to allow endovascular access of the intracranial ICA per investigator judgement. Indicators of vessel tortuosity include but are not limited to the presence of carotid loops and type 3 aortic arches.
  10. Evidence of tandem lesions, including complete occlusion, high grade stenosis or arterial dissection in the extracranial or internal carotid artery (ICA), requiring treatment or preventing access to thrombus.
  11. Subjects with known or suspected underlying intracranial atherosclerotic lesions responsible for the target occlusion.
  12. Subjects with occlusions in multiple vascular territories (e.g., bilateral anterior circulation, or anterior/posterior circulation).
  13. Anatomical or physiological restrictions (e.g., severe stenosis, vasospasm, high tortuosity, etc.) detected via angiogram likely to result in an inability to position the guide catheter or to deploy the ANA or intermediate catheter in the targeted ICA segment with acceptable vessel diameter as defined in the Instructions for Use.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: ANA Funnel Catheter Group
Mechanical thrombectomy using a stent retriever delivered by the ANA device.
Mechanical thrombectomy using a stent retriever delivered by the ANA device that enables local flow restriction when deployed.
Active Comparator: Control Group
Mechanical thrombectomy using a stent retriever delivered by an approved guide catheter.
Mechanical thrombectomy using a stent retriever delivered by an approved guide catheter with or without an intermediate catheter and aspiration per conventional techniques.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of subjects with "near-complete" reperfusion after one thrombectomy pass (FPE, eTICI 2c-3, extended Thrombolysis in Cerebral Infarction scale) in the target vessel after one reperfusion attempt.
Time Frame: intra-operative
Reperfusion to be assessed by an independent Core Lab.
intra-operative
Rate of symptomatic intracranial hemorrhage (sICH), attributable to the device or procedure.
Time Frame: Within 24 hours of the procedure
Extent of hemorrhage to be assessed by an independent Core Lab, symptoms to be assessed by the Data Monitoring Committee (DMC).
Within 24 hours of the procedure

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Adnan Siddiqui, MD, PhD, FAHA, Jacobs School of Medicine & Biomedical Sciences

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

September 1, 2024

Primary Completion (Estimated)

December 1, 2025

Study Completion (Estimated)

March 1, 2026

Study Registration Dates

First Submitted

April 11, 2024

First Submitted That Met QC Criteria

April 15, 2024

First Posted (Actual)

April 17, 2024

Study Record Updates

Last Update Posted (Actual)

April 17, 2024

Last Update Submitted That Met QC Criteria

April 15, 2024

Last Verified

April 1, 2024

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Acute Ischemic Stroke From Large Vessel Occlusion

Clinical Trials on ANA Funnel Catheter

3
Subscribe